Contact Us
Drug Search Results
More Filters [+]

BMS-986497

Alternative Names: BMS-986497, BMS 986497, BMS986497, ORM-6151, ORM6151, ORM 6151
Latest Update: 2024-06-27
Latest Update Note: Clinical Trial Update

Product Description

ORM-6151/BMS-986497 is a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader initially developed by Orum Therapeutics for the treatment of acute myeloid leukemia (AML) and other CD33-expressing malignancies. (Sourced from: https://www.orumrx.com/pipeline-page)

Mechanisms of Action: GSPT1 Degrader,CD33 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BMS-986497

Countries in Clinic: Canada, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CA235-0001

P1

Recruiting

Acute Myeloid Leukemia|Preleukemia|Myelodysplastic Syndrome

2027-02-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions